Go to main content
Global

Product Overview

AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.

Intensive Care

Empesin®

Empesin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.

Drug Facts
Active Ingredient
Agripressin
Intensive Care

Esmolol Amomed

Esmocard® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.

Drug Facts
Active Ingredient
Esmolol
Intensive Care

Nalbuphin Amomed

Drug Facts
Active Ingredient
Intensive Care

Naloxon Amomed

"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."

Drug Facts
Active Ingredient
Naloxone
Intensive Care

Noradrenalin Orpha

Drug Facts
Active Ingredient
Intensive Care

PONVeridol®

Adepend is used as part of a comprehensive treatment program against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.

Drug Facts
Active Ingredient
Droperidol
Intensive Care

Rapibloc ®

Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.

Drug Facts
Active Ingredient
Landiolol
Intensive Care

Siroctid®

Drug Facts
Active Ingredient